Skip to content

A clinical trial to trial to see if a medical device called the RURAL AT HOME EMBRACE INFANT WARMER can help maintain normal body temperature in low-birth-weight neonates, when used at home.

A randomized, open-label, active controlled study to determine the safety and efficacy of the rural-at-home Embrace� infant warmer (REIW) in maintaining thermo-stability (36.5 ° C to 37.5° C), of low-birth-weight (LBW) neonates when used in a home setting.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/11/002125
Enrollment
120
Registered
2011-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Maintenance of thermostability of low-birth-weight neonates in the home setting.

Interventions

Intervention1: Rural at home embrace infant warmer: Rural at home embrace infant warmer to maintain thermostability in the range of 36.5 to 37.5 degree celcius that lasts for 11 days as measured by ax

Sponsors

Cambree Life Improvement Technologies Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Parental agreement to participate, as documented on ICF. 2)Participant age of minimum 6 hours at the time of screening. 3)Low-birth-weight neonates (weight more than or equal to 1500 grams to less than 2500 grams at time of screening) 4)Neonate body temperature not less than 36.0 oC 5)Neonate gestated for minimum 32 weeks.

Exclusion criteria

Exclusion criteria: 1)Malformation that adversely affects the temperature of the neonate 2)Parental refusal to participate. 3)Body temperature below 36.0 oC 4)Cardio respiratory distress 5)External supply of oxygen or intravenous fluids.

Design outcomes

Primary

MeasureTime frame
1. Maintaining thermo-stability (36.5 degree Celsius to 37.5 degree Celsius), by the participating neonate at the end of the study treatment phase, as determined by axillary or skin care method. (D0 to D10) 2. Achievement of thermo-stability (36.5 degree Celsius to 37.5 degree Celsius), by the participating neonate at the end of the study treatment phase, as determined by axillary or skin care method. (D0 to D10) 3. Number of occurrence of adverse events and serious adverse events. (D0 to D10) Timepoint: 1) Day 0 to Day 10 2) Day 0 to Day 10 3) Day 0 to Day 10

Secondary

MeasureTime frame
1)Neonate comfort in the bag. 2)Ease of use by the neonate attendant/care giver Timepoint: During the hospital follow up phase (D 11)

Countries

India

Contacts

Public ContactDR SUDHIR BORGONHA

Cambree Life Improvement Technologies Private Limited

rpanicker@embraceinnovations.com09538768690

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026